At Alzheon, we have built an innovative drug development platform that allows us to identify and assess drug candidates based on their ability to target beta amyloid and disrupt disease pathogenesis, to improve the memory and cognitive deficits of Alzheimer’s disease as well as other brain disorders. We have developed a thorough understanding of the formation of toxic soluble beta amyloid oligomers, and the mechanism of action of the small molecule drug candidates we design to intervene in the formation of oligomers before they impart deleterious effects.
Applying a Precision Medicine approach, we have combined deep experience in neurology drug development, as well as insights into beta amyloid biology, to establish a proprietary platform for the discovery and advancement of beta amyloid-targeted small molecules. Our platform includes:
- An established and growing library of >5,000 proprietary beta amyloid-targeted small molecules
- Candidates that prevent pathogenic misfolding of proteins causing neurodegenerative disorders
- Fundamental knowledge of the protein aggregation process to identify compounds that specifically bind and block the critical steps in formation of toxic oligomers
- State-of-the-art clinical development approaches to improve the likelihood of success, including clinical studies designed with insights into patient subpopulations, clinical endpoints, and biomarkers
While are currently developing beta amyloid therapies for Alzheimer’s disease, amyloid biology also plays a critical role in other brain diseases as well as aging process. Population aging and associated disorders have become a major threat to human health and the focus of our platform in the future will be brain health, memory and aging.